Drug Profile

Ozarelix

Alternative Names: D-63153; SPI-153

Latest Information Update: 22 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AEterna Zentaris Inc
Developer AEterna Zentaris Inc; Assertio Therapeutics
Class Antineoplastics; Peptides
Mechanism of Action Gonadotropin releasing hormone inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Prostate cancer
No development reported Endometriosis
Discontinued Alzheimer's disease; Benign prostatic hyperplasia

Most Recent Events

16 Jun 2026 Assertio Therapeutics has been acquired by Zydus Lifesciences
06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in USA (IM, Injection)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com